Latest Regulatory News

Mayne Pharma has firmly rejected Cosette Pharmaceuticals’ notice attempting to terminate their merger agreement, setting the stage for a potential courtroom showdown over the disputed deal.

Battery Age Minerals Ltd (ASX, BM8) has responded to an ASX price query following a notable jump in its share price and trading volume, attributing the activity to recent public communications and exploration progress.

Xstate Resources has disposed of its 20% stake in the Austrian Anshof project, eliminating liabilities and streamlining its portfolio ahead of a planned ASX re-listing and development of its Diona project in Queensland.

Nyrada has secured ethics approval to amend its Phase I clinical trial protocol for Xolatryp, allowing testing of higher doses and extended infusion times. This strategic move aims to refine dosing ahead of Phase II trials, with final Phase I results expected by September 2025.

Elph Investments has raised and finalised its off-market takeover bid for Engenco Limited shares at $0.31 per share, applying to all shareholders including those who already accepted. This move signals a decisive step in the ongoing acquisition process.

Keybridge Capital has lodged a formal complaint with the Takeovers Panel, alleging improper dilution of its voting power in Yowie Group via the HHY Fund ahead of a pivotal shareholder meeting.

QuickFee Limited has launched a A$1.5 million capital raising to fund expansion of its loan books in the US and Australia, following a quarter of record revenue and positive earnings before tax. The fintech also completed a major refinancing and revised its earnings guidance due to a credit impairment provision.

OncoSil Medical has launched a Security Purchase Plan offering discounted shares and free options to eligible shareholders, aiming to accelerate commercialization of its pancreatic cancer treatment device.

Anax Metals has issued a detailed clarification on its recent $3.3 million convertible note placement with Mineral Development Partners, addressing inconsistencies in shareholder approval disclosures and announcing strengthened compliance measures.

National Storage REIT has partnered with GIC to invest $228 million in a second tranche of self-storage development assets, reaffirming its FY25 earnings guidance and strategic growth plans.

Chimeric Therapeutics has secured FDA Fast Track designation for its CHM CDH17 CAR-T therapy targeting gastroenteropancreatic neuroendocrine tumours, accelerating its path toward regulatory approval and patient access.

CZR Resources has secured Foreign Investment Review Board approval for the sale of its Robe Mesa Iron Ore Project, marking a significant step toward closing the A$75 million transaction.